

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司

## SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*

**(Stock Code: 01099)**

### **CLOSURE OF THE REGISTER OF MEMBERS**

Reference is made to the announcement (the “**Announcement**”) of the Sinopharm Group Co. Ltd. (the “**Company**”) dated 22 October 2020 in relation to, among other things, entering into the 2020 Procurement Framework Agreement between the Company and CNPGC and the 2020 Financial Service Framework Agreement between the Company and Sinopharm Group Finance Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company proposed to convene and hold an extraordinary general meeting on Friday, 18 December 2020 to seek the approval of the Shareholders with respect to the continuing connected transactions contemplated under the 2020 Procurement Framework Agreement and the proposed annual caps thereof and the deposit services under the 2020 Financial Services Framework Agreement and the proposed annual caps thereof. A circular containing, among other things, details of the continuing connected transactions contemplated under the 2020 Procurement Framework Agreement and the proposed annual caps thereof and the deposit services under the 2020 Financial Services Framework Agreement and the proposed annual caps thereof together with a notice convening the extraordinary general meeting is expected to be despatched to the Shareholders on or before 3 December 2020.

For the purpose of holding the extraordinary general meeting, the register of members of the Company (the “**Register**”) will be closed from Wednesday, 18 November 2020 to Friday, 18 December 2020 (both days inclusive) during which period no transfer of shares of the Company will be registered.

In order to be qualified to attend and vote at the extraordinary general meeting, for holders of H shares of the

Company, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at Room 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as practicable, and in any event no later than 4:30 p.m. on Tuesday, 17 November 2020.

The Shareholders whose names appear on the Register on Wednesday, 18 November 2020 are entitled to attend and vote at the extraordinary general meeting.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Li Zhiming**  
Chairman

Shanghai, the PRC  
3 November 2020

*As at the date of this announcement, the executive Directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive Directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive Directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.*

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*